DUMMYHDLVR - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.1
| Stock Code | DUMMYHDLVR | Market Cap | N/A | Current Price | N/A | High / Low | N/A |
| Stock P/E | N/A | Book Value | N/A | Dividend Yield | N/A | ROCE | N/A |
| ROE | N/A | Face Value | N/A | DMA 50 | N/A | DMA 200 | N/A |
| Chg in FII Hold | N/A | Chg in DII Hold | N/A | PAT Qtr | N/A | PAT Prev Qtr | N/A |
| RSI | N/A | MACD | N/A | Volume | N/A | Avg Vol 1Wk | N/A |
| Low price | N/A | High price | N/A | PEG Ratio | N/A | Debt to equity | N/A |
| 52w Index | N/A | Qtr Profit Var | N/A | EPS | N/A | Industry PE | N/A |
📊 Dr. Reddy’s Laboratories (DRREDDY) shows moderate intraday potential today. RSI at 47.2 indicates neutral momentum, while MACD is slightly positive (6.91), suggesting mild bullish sentiment. Current price (1,274 ₹) is near the 50 DMA (1,273 ₹) and above the 200 DMA (1,256 ₹), reflecting short-term stability. Volume (10,47,383) is slightly below average (11,83,492), limiting breakout potential but still providing liquidity.
💡 Optimal Buy Price: 1,270–1,280 ₹ (near support)
🎯 Profit-Taking Levels: 1,300–1,320 ₹ (short-term resistance)
🛑 Stop-Loss: 1,255 ₹ (recent low)
⏳ If already holding intraday: Exit near 1,300–1,310 ₹ if momentum weakens or if price fails to sustain above 1,280 ₹ with volume confirmation.
Positive
- Strong ROCE (25.8%) and ROE (20.3%) indicate efficient capital use.
- EPS of 55.6 ₹ supports earnings strength.
- PEG ratio of 0.47 suggests reasonable valuation relative to growth.
- DII holdings increased (+2.45%), showing strong domestic institutional support.
- 52-week performance is strong (+70.8%).
Limitation
- Quarterly PAT dropped sharply from 387 Cr. to 90.6 Cr. (-89.3%).
- FII holdings decreased (-2.35%), reflecting reduced foreign investor confidence.
- Volume below average, limiting intraday opportunities.
Company Negative News
- No major negative news reported, but steep decline in quarterly profits weighs on sentiment.
Company Positive News
- Strong ROCE and ROE highlight operational efficiency.
- DII inflows indicate domestic confidence in the company.
Industry
- Industry P/E at 27.2 is slightly higher than Dr. Reddy’s 22.9, suggesting fair valuation.
- Pharmaceutical sector remains resilient, supported by global demand but faces pricing and regulatory pressures.
Conclusion
✅ Dr. Reddy’s Laboratories shows moderate intraday potential with stable price action near key averages and mild bullish signals from MACD. Short-term traders may attempt a trade near 1,270–1,280 ₹ with a stop-loss at 1,255 ₹ and target exits around 1,300–1,320 ₹. Conservative traders should wait for stronger volume confirmation before entering aggressive intraday positions.